{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-021973","form_type":"8-K","ticker":null,"cik":"0001651407","company_name":"Checkpoint Therapeutics, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.313621+00:00","generated_at":"2026-05-25T01:35:44.603005+00:00","sec_items":["1.01","5.03","8.01","9.01","5.02"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Checkpoint Therapeutics to be acquired by Sun Pharma for $4.10/share plus CVR","bullets":["Total transaction value up to ~$416M; $4.10 per share cash plus CVR up to $0.70.","CVR pays up to $0.70 based on EMA approval of cosibelimab in EU or key countries within 36 months of filing.","Fortress Biotech (11.2% of shares, majority voting power) agrees to vote in favor and waive appraisal.","Merger subject to stockholder vote, HSR clearance, and other conditions; termination fee of $12.5M.","Company adopted exclusive forum bylaw for derivative and Securities Act claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-021973","json":"https://secwatch.observer/filing/0001104659-25-021973.json","markdown":"https://secwatch.observer/filing/0001104659-25-021973.md","text":"https://secwatch.observer/filing/0001104659-25-021973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651407/000110465925021973/0001104659-25-021973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651407/000110465925021973/tm258581d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:35:44.603005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b15f415716f704cd9da3fa3ce30eefff87ee9549","claim":"Checkpoint Therapeutics, Inc.: The board adopted an amendment to the bylaws establishing exclusive forum provisions for certain internal and securities claims, effective upon execution of the Merger Agreement (effective 2025-03-09).","evidence_excerpt":"the Company Board adopted an amendment (the “ Bylaws Amendment ”) to the bylaws of the Company (the “ Bylaws ”), which became effective concurrently with the execution of the Merger Agreement.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651407/000110465925021973/0001104659-25-021973-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-03-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}